Biogen Idec News

Ireland's Elan and U.S. drugmaker Biogen Idec have amended the label of their multiple sclerosis drug Tysabri to reflect the increased risk of contracting a potentially deadly brain infection, Elan said in a statement on Saturday.

Biogen Idec By Jefferies & Company WE ARE UPGRADING Biogen to Buy from Hold on valuation; maintaining our price target of $50, about 19% upside to current share price.

"We are executing on our development programs while remaining vigilant on cost containment and expense management," said Faheem Hasnain, president and chief executive officer of Facet Biotech.

Our analysts have issued complimentary analysis on the following six companies: New York Community Bancorp Inc.

Unsubstantiated whisperings about Biogen Idec and its controversial multiple sclerosis drug took an ugly turn to the truth on Thursday when European regulators disclosedA another new case of progressive multifocal leukoencephalopathy , a serious brain infection known as PML, in a relapsed MS patient receiving Tysabri infusions.

Today the EMEA, the European equivalent of the U.S. Food and Drug Administration, released a statement indicating that one of its advisory committees was launching a review of the risks and benefits of Tysabri in light of 23 confirmed cases of PML that it says have occurred since the drug has been on the market.

Thirteen was a good number for Biogen Idec and Elan . Twenty-three? Not so much.

Biogen Idec 's key multiple sclerosis drug is in the news again, as the European Medicines Agency has started a safety review of Tysabri , citing more confirmed cases of a rare - but potentially fatal - viral infection of the brain, called progressive multifocal leukoencephalopathy , previously linked to the drug.

Shares of Biogen Idec fell Friday as European regulators investigate reports of 23 cases of Tysabri patients with a potentially fatal brain infection.

Total revenue rose 6% thanks to Tysabri's slow but steady growth; Biogen Idec spilled the beans on that earlier in the week.

InvestorSoup.com announces an investment report featuring Inovio Biomedical Corp.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Coca-Cola's net income was $1.896 billion for the quarter, up from $1.89 billion a year earlier.

Biogen Idec Inc. Q3 2009 Earnings Call October 20, 2009 8:30 am ET Executives James C. Mullen - President, Chief Executive Officer, Director Paul J. Clancy - Chief Financial Officer, Executive Vice President - Finance Robert A. Hamm - Chief Operating Officer Alfred Sandrock, MD, PhD - SVP Neurology R&D Analysts May-Kin Ho - Goldman Sachs Geoff ...

Biogen Idec says its profit jumped 34 percent in the third quarter due to lower amortization costs and increased sales of its multiple sclerosis drug Tysabri.

Elan Corporation, plc and Biogen Idec today announced multiple presentations at the American College of Gastroenterology Annual Scientific Meeting, taking place October 23-28 in San Diego.

Biogen Idec and Biovitrum AB today announced that they plan to advance the companiesa long-acting, fully-recombinant Factor IX Fc fusion protein into a registrational clinical trial in hemophilia B patients.

CAMBRIDGE, Mass.-- --Biogen Idec Inc. announced today that it has extended the tender offer by its wholly owned subsidiary, FBC Acquisition Corp., to purchase all of the ou... BASKING RIDGE, N.J.-- --Axion International Holdings, Inc.

SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. - Genentech, Inc. a wholly-owned member of the Roche Group , and Biogen Idec announced today that the companies received a Complete Response from the U.S. Food and Drug Administration for a supplemental Biologics License Application for Rituxan plus methotrexate in patients with moderately-to-severely ...

Biotech has traditionally been a sector that has fared better than most during economic downturns.